Guinguis Rami, Ruiz María Isabel, Rada Gabriel
Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile; Proyecto Epistemonikos, Santiago, Chile. Email:
Proyecto Epistemonikos, Santiago, Chile; Departamento de Psiquiatría, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
Medwave. 2017 Aug 9;17(7):e7010. doi: 10.5867/medwave.2017.07.7010.
Cannabidiol has recently been proposed as an antipsychotic for schizophrenia. However, its clinical use and safety is controversial. To answer this question, we used Epistemonikos, the largest database of systematic reviews in health, which is maintained by screening multiple information sources, including MEDLINE, EMBASE, Cochrane, among others. We identified six systematic reviews incorporating four primary studies overall, including two randomized trials. We extracted data from the systematic reviews, reanalyzed data from primary studies, conducted a meta-analysis and generated a summary of findings table using the GRADE approach. We concluded cannabidiol probably does not improve symptoms in schizophrenia and leads to frequent side effects.
大麻二酚最近被提议作为治疗精神分裂症的抗精神病药物。然而，其临床应用和安全性存在争议。为回答这个问题，我们使用了Epistemonikos，这是健康领域最大的系统评价数据库，通过筛选包括MEDLINE、EMBASE、Cochrane等在内的多个信息来源来维护。我们识别出六项系统评价，总共纳入四项主要研究，其中包括两项随机试验。我们从系统评价中提取数据，重新分析主要研究的数据，进行荟萃分析，并使用GRADE方法生成结果总结表。我们得出结论，大麻二酚可能无法改善精神分裂症的症状，并且会导致频繁的副作用。
